Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | USP14 | P54578 | 2/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29812272 | 0.87 | L3MBTL1 (0.62) | L3MBTL1NOTUMKDM4EMAPTGAA | |
| SCHEMBL680088 | 0.86 | ALDH1A1 (0.54) | L3MBTL1NOTUMKDM4EMAPTGAA | |
| SCHEMBL6751094 | 0.85 | NOTUM (0.57) | L3MBTL1NOTUMKDM4EMAPTGAA | |
| SCHEMBL9251071 | 0.84 | NOTUM (0.56) | L3MBTL1NOTUMKDM4EMAPTGAA | |
| SCHEMBL23147902 | 0.82 | MYC (0.44) | L3MBTL1NOTUMKDM4EMAPTMEN1 | |
| SCHEMBL29812174 | 0.82 | MYC (0.44) | L3MBTL1NOTUMKDM4EMAPTMEN1 | |
| SCHEMBL680212 | 0.82 | L3MBTL1 (0.56) | L3MBTL1NOTUMKDM4EMAPTMEN1 | |
| SCHEMBL25234474 | 0.80 | L3MBTL1 (0.42) | L3MBTL1NOTUMKDM4ESMN1; SMN2LMNA | |
| SCHEMBL11462311 | 0.79 | NOTUM (0.59) | L3MBTL1NOTUMKDM4EALDH1A1LMNA | |
| SCHEMBL11623203 | 0.79 | NOTUM (0.66) | L3MBTL1NOTUMKDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114787144-A | Pyridone compounds and methods for modulating protein kinases | 埃克塞里艾克西斯公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021062245-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | EXELIXIS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-102105462-B | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2014-07-23 | — | — | CN | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| CN-102105462-A | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2011-06-22 | — | — | CN | disclosed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | L3MBTL1 3212/4885NOTUM 1749/4885KDM4E 947/4885 |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | L3MBTL1 461/4885NOTUM 3269/4885KDM4E 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.